(Q39009632)

English

Direct-acting antiviral drug approvals for treatment of chronic hepatitis C virus infection: Scientific and regulatory approaches to clinical trial designs

scientific article published on 7 May 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

8 September 2017

Direct-acting antiviral drug approvals for treatment of chronic hepatitis C virus infection: Scientific and regulatory approaches to clinical trial designs (English)

1 reference

Europe PubMed Central

8 September 2017

0 references

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

author name string

Poonam Mishra

1

1 reference

Europe PubMed Central

8 September 2017

Jeffrey Murray

2

1 reference

Europe PubMed Central

8 September 2017

Debra Birnkrant

3

1 reference

Europe PubMed Central

8 September 2017

language of work or name

0 references

publication date

7 May 2015

1 reference

Europe PubMed Central

8 September 2017

1 reference

Europe PubMed Central

8 September 2017

62

1 reference

Europe PubMed Central

8 September 2017

4

1 reference

Europe PubMed Central

8 September 2017

1298-1303

1 reference

Europe PubMed Central

8 September 2017

Diagnosis, management, and treatment of hepatitis C: an update

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27880

21 January 2018

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27880

21 January 2018

Boceprevir dosing for late responders and null responders: the role of bridging data between treatment-naïve and -experienced subjects

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27880

21 January 2018

FDA perspective on sofosbuvir therapy for patients with chronic hepatitis C virus genotype 1 infection who did not respond to treatment with pegylated interferon and ribavirin

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27880

21 January 2018

A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27880

21 January 2018

A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27880

21 January 2018

Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27880

21 January 2018

Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27880

21 January 2018

Development of novel agents for the treatment of chronic hepatitis C infection: Summary of the FDA Antiviral Products Advisory Committee recommendations

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27880

7 January 2021

based on heuristic

inferred from DOI database lookup

Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27880

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HEP.27880

1 reference

Europe PubMed Central

8 September 2017

1 reference

Europe PubMed Central

8 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39009632&oldid=1802031378"